fda declaratory order semaglutide shortage resolved feb 21 2025 february The FDA has issued a warning to Compounded Semaglutide & Tirzepatide 2025: – FDA clarifies policies for compounders

The severity, distribution, and specific characteristics of lesions and associated comorbidities inform the selection of therapeutic modalities

A 2022 meta-analysis published in Frontiers in Pharmacology pooled 37 randomized controlled trials covering 3,048 type 2 diabetes patients and found berberine reduced fasting plasma glucose by 0.82 mmol/L, HbA1c by 0.63%, and 2-hour postprandial glucose by 1.16 mmol/L

In a 2017 study, a nanomedicine formulation of GLP-1 was used to treat dextran sulfate sodium (DSS)-induced colitis in mice

Quick Answer: Small air bubbles in GLP-1 injection pens are safe and pose virtually no health risk because subcutaneous injections deposit medication into tissue, not blood vessels, where air is harmlessly absorbed